Satumomab-Y-90

N/A

Report date: 2025/12/01 17:17:09

Base Information

Drug NameSatumomab-Y-90

Drug Alias Namesatumomab Y 90CYT-103-Y90

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murineBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Nuclides > Yttrium > 90Y +[5]

Mechanisms of ActionTumor-associated glycoprotein 72 binders

TargetsTumor-associated glycoprotein 72

Therapy Area/IndicationsOvarian NeoplasmsColorectal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesCytogen Corp

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCytogen Corp

Active IndicationsN/A

Inactive IndicationsOvarian NeoplasmsColorectal Neoplasms

Other Information

ATC CodeN/A